Your browser doesn't support javascript.
loading
Effects of a low FODMAP diet on gut microbiota in individuals with treated coeliac disease having persistent gastrointestinal symptoms - a randomised controlled trial.
Herfindal, Anne Mari; van Megen, Frida; Gilde, Mari K O; Valeur, Jørgen; Rudi, Knut; Skodje, Gry I; Lundin, Knut E A; Henriksen, Christine; Bøhn, Siv Kjølsrud.
  • Herfindal AM; Department of Chemistry, Biotechnology and Food Sciences, Norwegian University of Life Sciences, Ås, Norway.
  • van Megen F; KG Jebsen Coeliac Disease Research Centre, University of Oslo, Oslo, Norway.
  • Gilde MKO; Unit for Clinical Nutrition, Division of Cancer Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
  • Valeur J; Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.
  • Rudi K; Department of Chemistry, Biotechnology and Food Sciences, Norwegian University of Life Sciences, Ås, Norway.
  • Skodje GI; Unger-Vetlesen Institute, Lovisenberg Diaconal Hospital, Oslo, Norway.
  • Lundin KEA; Department of Chemistry, Biotechnology and Food Sciences, Norwegian University of Life Sciences, Ås, Norway.
  • Henriksen C; Healthy Life Centre, Municipality of Nes, Nes, Norway.
  • Bøhn SK; KG Jebsen Coeliac Disease Research Centre, University of Oslo, Oslo, Norway.
Br J Nutr ; 130(12): 2061-2075, 2023 12 28.
Article en En | MEDLINE | ID: mdl-37272479
ABSTRACT
Individuals with coeliac disease (CeD) often experience gastrointestinal symptoms despite adherence to a gluten-free diet (GFD). While we recently showed that a diet low in fermentable oligo-, di-, monosaccharides and polyols (FODMAP) successfully provided symptom relief in GFD-treated CeD patients, there have been concerns that the low FODMAP diet (LFD) could adversely affect the gut microbiota. Our main objective was therefore to investigate whether the LFD affects the faecal microbiota and related variables of gut health. In a randomised controlled trial GFD-treated CeD adults, having persistent gastrointestinal symptoms, were randomised to either consume a combined LFD and GFD (n 39) for 4 weeks or continue with GFD (controls, n 36). Compared with the control group, the LFD group displayed greater changes in the overall faecal microbiota profile (16S rRNA gene sequencing) from baseline to follow-up (within-subject ß-diversity, P < 0·001), characterised by lower and higher follow-up abundances (%) of genus Anaerostipes (Pgroup < 0·001) and class Erysipelotrichia (Pgroup = 0·02), respectively. Compared with the control group, the LFD led to lower follow-up concentrations of faecal propionic and valeric acid (GC-FID) in participants with high concentrations at baseline (Pinteraction ≤ 0·009). No differences were found in faecal bacterial α-diversity (Pgroup ≥ 0·20) or in faecal neutrophil gelatinase-associated lipocalin (ELISA), a biomarker of gut integrity and inflammation (Pgroup = 0·74), between the groups at follow-up. The modest effects of the LFD on the gut microbiota and related variables in the CeD patients of the present study are encouraging given the beneficial effects of the LFD strategy to treat functional GI symptoms (Registered at clinicaltrials.gov as NCT03678935).
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad Celíaca / Síndrome del Colon Irritable / Microbioma Gastrointestinal Tipo de estudio: Clinical_trials / Diagnostic_studies Límite: Adult / Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad Celíaca / Síndrome del Colon Irritable / Microbioma Gastrointestinal Tipo de estudio: Clinical_trials / Diagnostic_studies Límite: Adult / Humans Idioma: En Año: 2023 Tipo del documento: Article